FORTRESS BIOTECH INC (FBIO)
US34960Q3074 - Common Stock
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
Extends maturity of long-term debt as Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs...
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
PDUFA goal date of December 28, 2024 set by FDA...
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy,...
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical...
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
MIAMI, July 05, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO; FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on...
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and...
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and...
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and...
Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring...
FBIO Stock Earnings: Fortress Biotech Beats EPS, Misses Revenue for Q1 2024
FBIO stock results show that Fortress Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
FBIO Stock Earnings: Fortress Biotech Beats EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fortress Biotech (NASDAQ:FBIO) just reported results for the first quarter of 2...
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially...
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter...
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted...
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted...
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET...
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.
FBIO Stock Earnings: Fortress Biotech Beats EPS, Beats Revenue for Q4 2023
FBIO stock results show that Fortress Biotech beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
FBIO Stock Earnings: Fortress Biotech Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fortress Biotech (NASDAQ:FBIO) just reported results for the fourth quarter of ...
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18...
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and...
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 ...
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024...
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET...
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical...
Fortress Biotech's Series A Preferred Stock Shares Cross 14.5% Yield Mark
Fortress Biotech to Participate in 36th Annual ROTH Conference
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on...
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that...
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for...
Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries
New York, Feb 2, 2024 - (Plato Data via 500NewsWire) -- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang.